Neurocrine Biosciences, Inc.
DE ˙ DB ˙ US64125C1099
134,65 € ↑0,30 (0,22%)
2026-06-03
AKTIENPREIS
SecurityDE:NB3 / Neurocrine Biosciences, Inc.
InstitutionAlliancebernstein L.p.
Latest Disclosed Ownership523,533 shares
Latest Disclosed Value $ 74,252,685
Alliancebernstein L.p. reports 5.75% decrease in ownership of NB3 / Neurocrine Biosciences, Inc.

On May 15, 2026 - Alliancebernstein L.p. filed a 13F-HR form disclosing ownership of 523,533 shares of Neurocrine Biosciences, Inc. (DE:NB3) valued at $58,504,813 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 555,494 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of -5.75% during the quarter. The current value of the position is $70,493,718 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 523,533 -31,961 -5.75 74,253 -5.75 0.0240
2026-02-17 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 555,494 -62,635 -10.13 78,786 -9.20 0.0249
2025-11-14 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 618,129 33,698 5.77 86,773 18.13 0.0273
2025-08-14 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 584,431 8,259 1.43 73,457 15.27 0.0240
2025-05-15 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 576,172 -1,444 -0.25 63,725 -19.18 0.0231
2025-02-12 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 577,616 -59,298 -9.31 78,845 7.44 0.0268
2024-11-14 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 636,914 15,049 2.42 73,385 -14.28 0.0246
2024-08-14 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 621,865 461,642 288.12 85,612 287.44 0.0299
2024-05-14 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 160,223 -13,405 -7.72 22,098 -3.41 0.0078
2024-02-14 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 173,628 24,868 16.72 22,877 36.70 0.0088
2023-11-14 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 148,760 10,677 7.73 16,736 28.52 0.0071
2023-08-15 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 138,083 -13,266 -8.77 13,021 -15.00 0.0053
2023-05-15 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 151,349 -15,512 -9.30 15,320 -23.13 0.0066
2023-02-15 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 166,861 11,693 7.54 19,930 20.93 0.0090
2022-11-15 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 155,168 6,541 4.40 16,480 13.75 0.0080
2022-08-15 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 148,627 -36,859 -19.87 14,488 -16.68 0.0066
2022-05-13 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 185,486 21,984 13.45 17,389 24.88 0.0067
2022-02-14 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 163,502 -7,748 -4.52 13,925 -15.22 0.0049
2021-11-10 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 171,250 18,279 11.95 16,425 10.33 0.0065
2021-07-30 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 152,971 -5,975 -3.76 14,887 -3.69 0.0060
2021-05-06 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 158,946 100,678 172.78 15,457 176.76 0.0068
2021-02-08 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 58,268 -639,914 -91.65 5,585 -91.68 0.0026
2020-11-12 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 698,182 -190,677 -21.45 67,137 -38.09 0.0361
2020-08-13 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 888,859 -244,961 -21.60 108,441 10.51 0.0637
2020-05-14 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,133,820 -106,113 -8.56 98,132 -26.37 0.0704
2020-02-18 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,239,933 -10,702 -0.86 133,280 18.27 0.0757
2019-11-14 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,250,635 47,231 3.92 112,695 10.92 0.0702
2019-08-14 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,203,404 98,945 8.96 101,603 4.42 0.0631
2019-05-14 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,104,459 34,243 3.20 97,303 27.32 0.0633
2019-02-13 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,070,216 -37,978 -3.43 76,424 -43.91 0.0567
2018-11-08 2018-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,108,194 -56,706 -4.87 136,252 19.06 0.0890
2018-08-13 2018-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,164,900 -108 -0.01 114,440 18.45 0.0797
2018-05-14 2018-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,165,008 215,680 22.72 96,614 31.17 0.0698
2018-02-13 2017-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 949,328 -56,319 -5.60 73,658 19.52 0.0527
2017-11-13 2017-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,005,647 48,972 5.12 61,626 40.04 0.0462
2017-08-10 2017-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 956,675 28,660 3.09 44,007 9.52 0.0340
2017-05-11 2017-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 928,015 -95,427 -9.32 40,183 1.45 0.0320
2017-02-13 2016-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,023,442 147,393 16.82 39,607 -10.72 0.0330
2016-11-10 2016-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 876,049 -228,466 -20.68 44,363 -11.63 0.0374
2016-08-11 2016-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,104,515 957,289 650.22 50,200 762.10 0.0432
2016-05-13 2016-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 147,226 4,680 3.28 5,823 -27.79 0.0049
2016-02-16 2015-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 142,546 -1,700 -1.18 8,064 40.49 0.0069
2016-02-12 2015-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 142,546 5,672
2015-11-13 2015-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 144,246 100 0.07 5,740 -16.62 0.0049
2015-08-14 2015-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 144,146 8,100 5.95 6,884 27.43 0.0057
2015-05-13 2015-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 136,046 10,200 8.11 5,402 92.17 0.0044
2015-02-13 2014-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 125,846 0 0.00 2,811 42.55 0.0023
2014-11-13 2014-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 125,846 0 0.00 1,972 5.62 0.0017
2014-08-13 2014-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 125,846 -104 -0.08 1,867 -7.94 0.0016
2014-05-13 2014-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 125,950 -6,964 -5.24 2,028 63.42 0.0018
2014-02-13 2013-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 132,914 538 0.41 1,241 -17.16 0.0011
2013-11-14 2013-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 132,376 -165 -0.12 1,498 -15.51 0.0015
2013-08-13 2013-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 132,541 132,541 1,773 0.0019
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.